Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wudi Lv Qi Bioengineering is a China-based microalgae biotechnology manufacturer focused on commercial production of spirulina, chlorella, and related algae-derived ingredients. The company appears to operate primarily as an industrial biotech and nutraceutical supplier rather than a drug-development biotech, with products used across health products, food ingredients, cosmetics, fine chemicals, and feed applications. Publicly available trade-directory and supplier materials describe the business as founded in 1995 in Wudi County, Shandong, with large-scale cultivation and processing capacity for spirulina and chlorella powders. Some sources also note academic and research collaborations in marine and agricultural sciences and describe the company as an experimental base associated with marine pharmaceutical engineering research. There is no clear evidence of a clinical-stage therapeutic pipeline; the business appears best characterized as a commercial algae ingredient and bioengineering company with healthcare-adjacent applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on WuliLvqi.